Evidence map›Paper›PMID 28149933›Full record

ArticleBladder cancer (Amsterdam, Netherlands)2017

Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study.

Friedrich-Carl von Rundstedt, Douglas A Mata, Oleksandr N Kryvenko, Anup A Shah, Iny Jhun, Seth P Lerner

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Friedrich-Carl von RundstedtScott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Department of Urology, Jena University Hospital, Friedrich-Schiller University, Jena, Germany.
Douglas A MataDepartment of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, MA, USA.
Oleksandr N KryvenkoDepartments of Pathology and Urology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine , FL, USA.
Anup A ShahDepartment of Urology, University of Pittsburgh Medical Center , PA, USA.
Iny JhunDepartment of Pathology, Brigham and Women's Hospital , Harvard Medical School, Boston, MA, USA.
Seth P LernerScott Department of Urology, Baylor College of Medicine , Houston, TX, USA.
Baylor College of Medicine · USBrigham and Women's Hospital · USUniversity of Miami · USUniversity of Pittsburgh Medical Center · US

Funding

Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
NCI NIH HHS P50 CA091846
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bladder cancerclinical stagingneoadjuvant chemotherapyrisk stratification

Identifiers

PMID28149933
PMCPMC5271426
OpenAlexW2552490149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.